EBV-transformed B-LCL, from the anti b2a2 peptide T-cell donor, transfected with full-length BCR-ABL^b2a2express p210 BCR-ABL protein, as determined by anti-ABL immunoblot, whereas cells transfected with an empty PDR2 vector do not. K562 and Tom-1 were used as positive controls for p210^BCR-ABL and p190^BCR-ABL, respectively. Allogeneic HLA-DR–matched BCR-ABL^b2a2 RT-PCR-positive leukemic cells from CML patients similarly express p210^BCR-ABL as shown for UPN 5831869, 3939610, and 3886117. BV173 was used as a p210b2a2-positive (but p145^ABL-negative8) control.